PFIZER INC 8-K

What Happened
Pfizer announced in an 8-K filed June 18, 2026 that Chief Financial Officer Dave Denton notified the company on June 16, 2026 that he will step down as CFO effective August 15, 2026 to pursue a professional opportunity in consumer goods. The company stated the departure is not related to Pfizer’s financial or operating results or any disagreements over accounting or reporting. Senior Vice President, Finance, Global Biopharmaceutical Business Cecile Guegan will serve as Interim Chief Financial Officer effective August 16, 2026 while Pfizer conducts a comprehensive search for a permanent successor.

Key Details

• Dave Denton notified Pfizer on June 16, 2026; effective departure date: August 15, 2026.
• Cecile Guegan named Interim CFO effective August 16, 2026; she joined Pfizer in 2005 and is 55 years old.
• Guegan has served as SVP, Finance, Global Biopharmaceutical Business since 2022; prior role included VP, Finance, Research & Development and Business Office (2020–2022).
• Company will undertake a comprehensive process to identify Denton’s successor; press release attached as Exhibit 99.1 to the 8-K.

Why It Matters
A CFO transition is material for investors because it affects financial leadership and reporting continuity. Pfizer’s statement that the departure is not related to financial results or disagreements is intended to reassure investors. The appointment of an experienced internal finance leader as interim CFO supports continuity while the company searches for a permanent replacement.